Formycon’s US Eylea Biosimilar Is Third In Six Weeks – But Timing Still Uncertain
Originator Regeneron Secures Further Injunctive Relief; Formycon Lodges Appeal
A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.
